vTv Therapeutics (VTVT) Stock: Buy, Sell, or Hold?
VTVT - vTv Therapeutics Inc. Class A Common Stock
$31.97
0.11 (0.35%)
â˛
5d:
-4.48%
30d:
+0.6%
90d:
+1.2%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When VTVT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VTVT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VTVT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VTVT is currently trading at $31.97, which is considered slightly low relative to its 30-day fair value range of $31.66 to $34.05.
Technical Outlook: Technically, VTVT is showing sideways momentum. The price is currently testing key support at $31.29. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VTVT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $54.71 (+71.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VTVT is showing sideways momentum. The price is currently testing key support at $31.29. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VTVT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $54.71 (+71.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$31.66 -
$34.05
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 71.1% below Wall St target ($54.71)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$31.66 -
$34.05
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$31.29
Resistance Level
$34.14
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.45
Wall Street Target
$54.71
(+71.1%)
Profit Margin
-12.9%
Share & Embed Analysis
Last updated: September 13, 2026 9:15 PM ET
Data refreshes hourly during market hours. Next update: 10:15 PM
Data refreshes hourly during market hours. Next update: 10:15 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VTVT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
